Compare Carnival Corp (CCL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs Sanofi SA — how do they compare? Carnival Corp trades at $27.92 (market cap $37.98B), while Sanofi SA trades at $43.59 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.7× Carnival Corp's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| CCL | SNY | |
|---|---|---|
Market Cap | $37.98B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $52.34 |
52-Week Low | $23.89 | $41.33 |
Enterprise Value | $61.91B | $124.19B |
Dividend Yield | 1.62% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $27.75, down 4.28% today, amid a bearish technical signal. The company shows strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, net income turning positive to $2.76B, and positive cash flow of $727M in 2025. Recent earnings beats and a 59.57% analyst buy rating support optimism, though technical indicators show near-term pressure with support at $27.
Outlook remains positive driven by record travel demand, fleet expansion, and debt reduction, with a consensus price target of $35.18 offering 27% upside. Key risks include fuel price volatility, economic sensitivity, and execution of growth plans amid competitive pressures.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
